• Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s unique approach to the psychedelics and health care sectors
  • Algernon Pharmaceuticals is a clinical stage pharmaceutical development company that investigates safe, already approved drugs and compounds for new disease applications
  • The company is advancing several compounds including Ifenprodil and DMT
  • Algernon is closing enrollment for a 20-patient Ifenprodil study
  • Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99

Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.

Algernon Pharmaceuticals is a clinical-stage pharmaceutical development company. Algernon investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon is currently advancing a number of compounds including Ifenprodil for the treatment of chronic cough and N, N-Dimethyltryptamine, or DMT, a hallucinogenic drug for stroke treatment.

Algernon is currently closing enrollment for a 20-patient Ifenprodil study in Australia and New Zealand.

Shares of Algernon Pharmaceuticals Inc. (AGN) are currently trading at $7.99.

More From The Market Online

Biotech company patenting world’s first AI voice test for substance abuse

Biotech company MindBio files a patent application for the world's first AI model to detect substance abuse though vocal analysis.

2 biotech stocks bridging the gap between unmet need and next-gen medicine

Exploring Lunai Bioworks and TheraCryf, two biotech stocks taking early strides towards improving the lives of tens of millions of patients.
The Market Online Video

One of the biggest opportunities in strategic minerals most investors don’t know about

Southern Energy completes a US$23.5M financing to reduce debt and drive production growth across its Gulf Coast natural gas assets.